The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
Open accessAbstract
BACKGROUND: Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment. METHODS: We conducted a randomized, double-blind trial in which adults with acute bacterial skin and skin-structure infections received either a single intravenous dose of 1200 mg of oritavancin or a regimen of intravenous vancomycin twice daily for 7 to 10 days. Three efficacy end points were tested for noninferiority. The primary composite end point was defined as cessation of spreading or reduction in lesion size, absence of fever, and no need for administration of a rescue antibiotic 48 to 72 hours after administration of oritavancin. Secondary end points were clinical cure 7 to 14 days after the end of treatment, as determined by a study investigator, and a reduction in lesion size of 20% or more 48 to 72 hours after administration of oritavancin. RESULTS: The modified intention-to-treat population comprised 475 patients who received oritavancin and 479 patients who received vancomycin. All three efficacy end points met the prespecified noninferiority margin of 10 percentage points for oritavancin versus vancomycin: primary end point, 82.3% versus 78.9% (95% confidence interval [CI] for the difference, -1.6 to 8.4 percentage points); investigator-assessed clinical cure, 79.6% versus 80.0% (95% CI for the difference, -5.5 to 4.7 percentage points); and proportion of patients with a reduction in lesion area of 20% or more, 86.9% versus 82.9% (95% CI for the difference, -0.5 to 8.6 percentage points). Efficacy outcomes measured according to type of pathogen, including methicillin-resistant Staphylococcus aureus, were similar in the two treatment groups. The overall frequency of adverse events was also similar, although nausea was more common among those treated with oritavancin. CONCLUSIONS: A single dose of oritavancin was noninferior to twice-daily vancomycin administered for 7 to 10 days for the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens. (Funded by the Medicines Company; SOLO I ClinicalTrials.gov number, NCT01252719.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Landrum, M. L., Neumann, C., Cook, C., Chukwuma, U., Ellis, M. W., Hospenthal, D. R., & Murray, C. K. (2012) · JAMA · doi:10.1001/jama.2012.7139 · Cited by 228
The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
Lee, B. Y., Singh, A., David, M. Z., Bartsch, S. M., Slayton, R. B., Huang, S. S., Zimmer, S. M., Potter, M. A., Macal, C. M., Lauderdale, D. S., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03914.x · Cited by 207
Jenkins, T. C., Sabel, A. L., Sarcone, E. E., Price, C. S., Mehler, P. S., & Burman, W. J. (2010) · Clinical Infectious Diseases · doi:10.1086/656431 · Cited by 182
Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R., & Moeck, G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00766-08 · Cited by 178
Self-citationOritavancin: Mechanism of Action
Zhanel, G. G., Schweizer, F., & Karlowsky, J. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir920 · Cited by 167
McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A. C., Sarmiento, I., Parr, T., & Moeck, G. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp126 · Cited by 138
Self-citationBelley, A. C., McKay, G. A., Arhin, F. F., Sarmiento, I., Beaulieu, S., Fadhil, I., Parr, T. R., & Moeck, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00760-10 · Cited by 120
Self-citationGarau, J., Ostermann, H., Medina, J., Avila, M. A. S., McBride, K., & Blasi, F. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12235 · Cited by 116
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Raff, A. B., & Kroshinsky, D. (2016) · JAMA · doi:10.1001/jama.2016.8825 · Cited by 452
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Metadata
- Authors
- Corey, G. R., Kabler, H., Mehra, P., Gupta, S., Overcash, J. S., Porwal, A., Giordano, P., Lucasti, C., Perez, A., Good, S., Jiang, H., Moeck, G., & O'Riordan, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-06-05
- Volume
- 370
- Issue
- 23
- Pages
- 2180-2190
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2161621663
- Cited by
- 305
- References
- 20
- FWCI
- 28.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. https://app.cochat.ai/papers/10.1056/nejmoa1310422
- The paper
- Corey, G. R., Kabler, H., Mehra, P., Gupta, S., Overcash, J. S., Porwal, A., Giordano, P., Lucasti, C., Perez, A., Good, S., Jiang, H., Moeck, G., & O'Riordan, W. (2014). Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1310422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.